No Zafgen IPO Yet; It Plans a $40M Crossover Round
This article was originally published in The Pink Sheet Daily
The private obesity company will do a mezzanine venture financing that brings in at least one public-oriented investor before it heads, presumably, toward an IPO. That round is slated to close in a month or so. Around the same time, Zafgen will present final Phase II data for its beloranib.
You may also be interested in...
Armed with cash from a robust M&A and a stock market boom, mutual and hedge funds are eagerly crossing over into mezzanine rounds for private biotechs and playing key roles in some of the year’s biggest venture financings.
Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?